PUBLICATION

Zebrafish screens for new colitis treatments - a bottom-up approach

Authors
Lee, J.A., Renshaw, S.A.
ID
ZDB-PUB-170209-16
Date
2017
Source
The FEBS journal   284: 399-401 (Review)
Registered Authors
Renshaw, Steve A.
Keywords
none
MeSH Terms
  • Dextran Sulfate
  • Animals, Genetically Modified
  • Anti-Inflammatory Agents/pharmacology*
  • Trinitrobenzenesulfonic Acid
  • Zebrafish
  • Animals
  • Disease Models, Animal
  • Neutrophils/drug effects
  • Neutrophils/immunology
  • Neutrophils/pathology
  • High-Throughput Screening Assays*
  • Dysbiosis/chemically induced
  • Dysbiosis/drug therapy*
  • Dysbiosis/immunology
  • Dysbiosis/pathology
  • Humans
  • Immunologic Factors/pharmacology*
  • Crohn Disease/chemically induced
  • Crohn Disease/drug therapy*
  • Crohn Disease/immunology
  • Crohn Disease/pathology
  • Colitis, Ulcerative/chemically induced
  • Colitis, Ulcerative/drug therapy*
  • Colitis, Ulcerative/immunology
  • Colitis, Ulcerative/pathology
  • Intestines/drug effects
  • Intestines/immunology
  • Intestines/pathology
PubMed
28168859 Full text @ FEBS J.
Abstract
Many factors interact in the development and progression of inflammatory bowel disease. This complexity demands a combination of methods to disentangle the pathology of this disease. As reported by Oehlers et al. in this issue, the zebrafish drug screen is one simple approach that could enable the elucidation of the pathways involved in IBD and ultimately the discovery of new therapeutics.
Genes / Markers
Figures
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Antibodies
Orthology
Engineered Foreign Genes
Mapping